



## Clinical trial results:

### An Open-Label Study with TMC278 25 mg q.d. in Combination with a Background Regimen

### Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in HIV-1 Infected Subjects,

### Who Participated in TMC278 clinical studies

#### Summary

EudraCT number	2010-021209-18
Trial protocol	BE DE GB SE ES IT DK AT NL
Global end of trial date	28 February 2020

#### Results information

Result version number	v1 (current)
This version publication date	26 February 2021
First version publication date	26 February 2021

#### Trial information

##### Trial identification

Sponsor protocol code	TMC278-TiDP6-C222
-----------------------	-------------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01266902
WHO universal trial number (UTN)	-

Notes:

##### Sponsors

Sponsor organisation name	Janssen Research & Development, LLC
Sponsor organisation address	920 Route 202, Raritan, United States, NJ 08869
Public contact	Janssen Research & Development, LLC, Clinical Registry group, ClinicalTrialsEU@its.jnj.com
Scientific contact	Janssen Research & Development, LLC, Clinical Registry group, ClinicalTrialsEU@its.jnj.com

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	28 February 2020
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	28 February 2020
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The objective of this study was to provide continued access to rilpivirine (RPV) for subjects who were randomized and treated with RPV in the Phase 2b (TMC278-C204 [C204]) or Phase 3 studies (TMC278-TiDP6-C209 [C209] and TMC278-TiDP6-C215 [C215]), and who, at the time of roll-over, experienced and were expected to continue experiencing clinical benefit from RPV treatment.

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practice (GCP) and applicable regulatory requirements. Serious Adverse Events (SAEs), Adverse events (AEs) leading to discontinuation, any grade 3/4 events of rash (irrespective of causality), AEs considered at least possibly related to RPV, human immunodeficiency virus (HIV)-related AEs, and pregnancies were collected from signing of the informed consent form (ICF) until the data cut-off date and were followed up by the investigator.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	25 February 2011
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy, Safety
Long term follow-up duration	9 Years
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 35
Country: Number of subjects enrolled	Australia: 11
Country: Number of subjects enrolled	Austria: 8
Country: Number of subjects enrolled	Belgium: 13
Country: Number of subjects enrolled	Canada: 21
Country: Number of subjects enrolled	Chile: 12
Country: Number of subjects enrolled	China: 26
Country: Number of subjects enrolled	Germany: 27
Country: Number of subjects enrolled	Denmark: 5
Country: Number of subjects enrolled	Spain: 14
Country: Number of subjects enrolled	France: 20
Country: Number of subjects enrolled	United Kingdom: 25
Country: Number of subjects enrolled	Italy: 10
Country: Number of subjects enrolled	Netherlands: 3

Country: Number of subjects enrolled	Puerto Rico: 7
Country: Number of subjects enrolled	Romania: 4
Country: Number of subjects enrolled	Russian Federation: 38
Country: Number of subjects enrolled	Sweden: 3
Country: Number of subjects enrolled	Thailand: 65
Country: Number of subjects enrolled	Taiwan: 2
Country: Number of subjects enrolled	United States: 85
Country: Number of subjects enrolled	South Africa: 48
Worldwide total number of subjects	482
EEA total number of subjects	107

Notes:

---

### **Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	479
From 65 to 84 years	3
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Total of 482 subjects were treated and 437 discontinued at data cut-off date (8 Feb 2018): 371 switched to commercially available RPV and 6 discontinued as they reached a virologic endpoint. At last visit of last subject (28 February 2020), out of 45 subjects 37 switched to commercially available RPV and 6 lost to follow-up.

### Period 1

Period 1 title	Period 1 (Main Study)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Blinding implementation details:

Not Applicable

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Rilpivirine (RPV) (TMC278-C204 [C204])
------------------	--

Arm description:

Subjects who rolled over from trial C204 continued to receive RPV 25 milligrams (mg) once daily (qd) in combination with an investigator-selected background regimen consisting of 2 nucleos(t)ide reverse transcriptase inhibitors (N[t]RTI)s starting Day 1.

Arm type	Experimental
Investigational medicinal product name	Rilpivirine
Investigational medicinal product code	
Other name	TMC278
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

RPV 25 mg oral tablets were administered orally.

Investigational medicinal product name	Nucleos(t)ide Reverse Transcriptase Inhibitors
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Two N(t)RTIs were administered as the investigator-selected background regimen.

<b>Arm title</b>	RPV (TMC278-TiDP6-C209 [C209] and TMC278-TiDP6-C215 [C215])
------------------	---

Arm description:

Subjects who rolled over from trial C209 and C215 continued to receive RPV 25 mg qd in combination with an investigator-selected background regimen consisting of 2 N(t)RTIs starting Day 1. In trial C209, the background regimen was fixed to tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) and in trial C215, the background regimen was selected by the investigator and contained either abacavir (ABC)/lamivudine (3TC), zidovudine (AZT)/3TC, or TDF/FTC.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Nucleos(t)ide Reverse Transcriptase Inhibitors
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Two N(t)RTIs were administered as the investigator-selected background regimen.

Investigational medicinal product name	Rilpivirine
Investigational medicinal product code	
Other name	TMC278
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

RPV 25 mg oral tablets were administered orally.

Number of subjects in period 1	Rilpivirine (RPV) (TMC278-C204 [C204])	RPV (TMC278-TiDP6- C209 [C209] and TMC278-TiDP6-C215 [C215])
	Started	119
Completed	89	282
Not completed	30	81
Consent withdrawn by subject	2	12
Adverse events	3	11
Continued to RPV treatment	11	34
Investigator's/Subject's decision	2	3
Subject non-compliant	3	7
Lost to follow-up	5	12
Lack of efficacy	4	2

## Period 2

Period 2 title	Period 2 (After Protocol Amendment 3)
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Blinding implementation details:

Not Applicable

## Arms

<b>Arm title</b>	RPV 25 mg (After Protocol Amendment 3)
Arm description: All subjects who were continued under a simplified study setting with only a minimum of study-related activities, as per Protocol Amendment 3 continued to receive RPV 25 mg and followed up for safety.	
Arm type	Experimental
Investigational medicinal product name	Rilpivirine
Investigational medicinal product code	
Other name	TMC278
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

RPV 25 mg oral tablets were administered orally.

<b>Number of subjects in period 2<sup>[1]</sup></b>	RPV 25 mg (After Protocol Amendment 3)
Started	45
Completed	37
Not completed	8
Consent withdrawn by subject	1
Adverse event, non-fatal	1
Lost to follow-up	6

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Only 45 subjects continued Rilpivirine (RPV) treatment per Protocol Amendment 3.

## Baseline characteristics

### Reporting groups

Reporting group title	Rilpivirine (RPV) (TMC278-C204 [C204])
-----------------------	--

Reporting group description:

Subjects who rolled over from trial C204 continued to receive RPV 25 milligrams (mg) once daily (qd) in combination with an investigator-selected background regimen consisting of 2 nucleos(t)ide reverse transcriptase inhibitors (N[t]RTI)s starting Day 1.

Reporting group title	RPV (TMC278-TiDP6-C209 [C209] and TMC278-TiDP6-C215 [C215])
-----------------------	---

Reporting group description:

Subjects who rolled over from trial C209 and C215 continued to receive RPV 25 mg qd in combination with an investigator-selected background regimen consisting of 2 N(t)RTIs starting Day 1. In trial C209, the background regimen was fixed to tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) and in trial C215, the background regimen was selected by the investigator and contained either abacavir (ABC)/lamivudine (3TC), zidovudine (AZT)/3TC, or TDF/FTC.

Reporting group values	Rilpivirine (RPV) (TMC278-C204 [C204])	RPV (TMC278-TiDP6-C209 [C209] and TMC278-TiDP6-C215 [C215])	Total
Number of subjects	119	363	482
Title for AgeCategorical Units: subjects			
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	118	361	479
From 65 to 84 years	1	2	3
85 years and over	0	0	0
Title for AgeContinuous Units: years			
median	40	39	
full range (min-max)	28 to 66	22 to 69	-
Title for Gender Units: subjects			
Female	41	84	125
Male	78	279	357

## End points

### End points reporting groups

Reporting group title	Rilpivirine (RPV) (TMC278-C204 [C204])
Reporting group description:	Subjects who rolled over from trial C204 continued to receive RPV 25 milligrams (mg) once daily (qd) in combination with an investigator-selected background regimen consisting of 2 nucleos(t)ide reverse transcriptase inhibitors (N[t]RTI)s starting Day 1.
Reporting group title	RPV (TMC278-TiDP6-C209 [C209] and TMC278-TiDP6-C215 [C215])
Reporting group description:	Subjects who rolled over from trial C209 and C215 continued to receive RPV 25 mg qd in combination with an investigator-selected background regimen consisting of 2 N(t)RTIs starting Day 1. In trial C209, the background regimen was fixed to tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) and in trial C215, the background regimen was selected by the investigator and contained either abacavir (ABC)/lamivudine (3TC), zidovudine (AZT)/3TC, or TDF/FTC.
Reporting group title	RPV 25 mg (After Protocol Amendment 3)
Reporting group description:	All subjects who were continued under a simplified study setting with only a minimum of study-related activities, as per Protocol Amendment 3 continued to receive RPV 25 mg and followed up for safety.

### Primary: Number of Subjects with Adverse Events (AEs)

End point title	Number of Subjects with Adverse Events (AEs) <sup>[1]</sup>
End point description:	An AE can be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product. The intent-to-treat (ITT) population included all subjects who have taken at least 1 dose of rilpivirine (RPV), regardless of their compliance with the protocol and adherence to the dosing regimen.
End point type	Primary
End point timeframe:	Up to 7 years

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No Inferential statistical analysis was planned for the Primary Endpoint.

End point values	Rilpivirine (RPV) (TMC278-C204 [C204])	RPV (TMC278-TiDP6-C209 [C209] and TMC278-TiDP6-C215 [C215])		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	119	363		
Units: Subjects	32	70		

### Statistical analyses

No statistical analyses for this end point

### Primary: Number of Subjects with Grade 3/4 Events of Rash irrespective of

## Causality

End point title	Number of Subjects with Grade 3/4 Events of Rash irrespective of Causality <sup>[2]</sup>
-----------------	---

End point description:

Subjects with grade 3/4 events of rash irrespective of causality were assessed. A grade 3 rash defined as diffuse macular, maculopapular or morbilliform rash with vesicles or limited number of bullae or; rash with superficial ulcerations of mucous membranes limited to 1 anatomical site or; rash with at least one of following: elevations in aspartate aminotransferase (AST)/alanine aminotransferase (ALT) more than 2\*baseline value and at least 5 times upper limit of normal; fever greater than (>) 38 degree celsius or 100 degree fahrenheit; eosinophils > 1000/millimeter (mm)<sup>3</sup>; serum sickness-like reaction. A grade 4 rash defined as following: extensive or generalized bullous lesions or; Stevens-Johnsons Syndrome (SJS) or ulceration of mucous membrane involving 2 or more distinct mucosal sites or toxic epidermal necrolysis. The ITT population included all subjects who have taken at least 1 dose of RPV, regardless of their compliance with the protocol and adherence to the dosing regimen.

End point type	Primary
----------------	---------

End point timeframe:

Up to 7 years

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No Inferential statistical analysis was planned for the Primary Endpoint.

End point values	Rilpivirine (RPV) (TMC278-C204 [C204])	RPV (TMC278-TiDP6-C209 [C209] and TMC278-TiDP6-C215 [C215])		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	119	363		
Units: Subjects	0	0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to Virologic Rebound

End point title	Time to Virologic Rebound
-----------------	---------------------------

End point description:

Time to virologic rebound was time to (first) human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) greater than or equal to (>=) 50 or >= 200 copies/milliliter (copies/mL). The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time. The ITT population included all subjects who have taken at least 1 dose of RPV, regardless of their compliance with the protocol and adherence to the dosing regimen.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 360

<b>End point values</b>	Rilpivirine (RPV) (TMC278-C204 [C204])	RPV (TMC278-TiDP6-C209 [C209] and TMC278-TiDP6-C215 [C215])		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	119	363		
Units: days				
arithmetic mean (standard error)				
>= 50 copies/mL	1670.6 (± 51.32)	1939.3 (± 52.43)		
>= 200 copies/mL	1901.3 (± 47.19)	1877.3 (± 25.93)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time To Treatment Failure

End point title	Time To Treatment Failure
End point description:	
Time to treatment failure was defined as time to virologic rebound (time to first HIV-1 RNA $\geq$ 50 or $\geq$ 200 copies/mL) or discontinuation for reason other than RPV having become commercially available in the participating country, whichever came first, calculated as the time (in days) from baseline until treatment failure. The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time. The ITT population included all subjects who have taken at least 1 dose of RPV, regardless of their compliance with the protocol and adherence to the dosing regimen.	
End point type	Secondary
End point timeframe:	
Up to Week 360	

<b>End point values</b>	Rilpivirine (RPV) (TMC278-C204 [C204])	RPV (TMC278-TiDP6-C209 [C209] and TMC278-TiDP6-C215 [C215])		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	119	363		
Units: days				
arithmetic mean (standard error)				
>= 50 copies/mL	1795.7 (± 70.03)	1694.1 (± 59.42)		
>= 200 copies/mL	1868.7 (± 63.29)	1637.5 (± 42.42)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in Cluster of Differentiation 4 (CD4+) Cell Count for Observed Case Approach until Week 336

End point title | Change from Baseline in Cluster of Differentiation 4 (CD4+) Cell Count for Observed Case Approach until Week 336

End point description:

Change from baseline in CD4+ cell count were reported for observed case approach. The immunologic assessment was determined by changes in Cluster of CD4+ cell count for observed case approach. The ITT population included all subjects who have taken at least 1 dose of RPV, regardless of their compliance with the protocol and adherence to the dosing regimen. Here 'n' (number analyzed) included all subjects who were evaluable for specified time point categories.

End point type | Secondary

End point timeframe:

Baseline up to Weeks 96, 192, 288, 336

End point values	Rilpivirine (RPV) (TMC278-C204 [C204])	RPV (TMC278-TiDP6-C209 [C209] and TMC278-TiDP6-C215 [C215])		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	119	363		
Units: cells/microliter (cells/mcL)				
arithmetic mean (standard error)				
Week 96: Observed Case (n= 74, 149)	72.63 (± 20.581)	55.91 (± 13.425)		
Week 192: Observed Case (n= 68, 100)	148.76 (± 24.111)	132.73 (± 21.989)		
Week 288: Observed Case (n= 45, 89)	122.29 (± 29.628)	101.50 (± 24.108)		
Week 336: Observed Case (n= 12, 30)	161.73 (± 39.851)	76.49 (± 40.484)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in CD4+ Cell Count for Non-Completer Equals Failure (NC=F) Approach until Week 336

End point title | Change from Baseline in CD4+ Cell Count for Non-Completer Equals Failure (NC=F) Approach until Week 336

End point description:

Change from baseline in CD4+ cell count were reported for NC=F approach (subjects who discontinued because RPV became commercially available or could be accessed through another source or because the subjects switched to other local [RPV-based] treatment options or local standard of care, were censored at that time; other subjects after discontinuation had their CD4+ values imputed with baseline value. Intermittently missing values were imputed with a last observation carried-forward approach). The ITT population included all subjects who have taken at least 1 dose of RPV, regardless of their compliance with the protocol and adherence to the dosing regime. Here 'n' (number analyzed) included all subjects who were evaluable for specified time point categories.

End point type | Secondary

End point timeframe:

Baseline up to weeks 96, 192, 288, 336

<b>End point values</b>	Rilpivirine (RPV) (TMC278-C204 [C204])	RPV (TMC278-TiDP6-C209 [C209] and TMC278-TiDP6-C215 [C215])		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	119	363		
Units: cells/mcL				
arithmetic mean (standard error)				
Week 96 (n= 79, 196)	69.76 (± 19.372)	42.19 (± 11.525)		
Week 192 (n= 77, 153)	133.56 (± 21.906)	91.69 (± 15.563)		
Week 288 (n= 61, 134)	92.12 (± 22.809)	63.33 (± 17.132)		
Week 336 (n= 27, 86)	70.69 (± 23.558)	49.24 (± 16.688)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects with Serious Adverse Events (SAEs)

End point title | Number of Subjects with Serious Adverse Events (SAEs)

End point description:

A SAE is any untoward medical occurrence that at any dose: results in death; is life threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect. The ITT population included all subjects who have taken at least 1 dose of RPV, regardless of their compliance with the protocol and adherence to the dosing regimen.

End point type | Secondary

End point timeframe:

Up to 7 years

<b>End point values</b>	Rilpivirine (RPV) (TMC278-C204 [C204])	RPV (TMC278-TiDP6-C209 [C209] and TMC278-TiDP6-C215 [C215])		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	119	363		
Units: Subjects	9	14		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects with AEs related to Rilpivirine (RPV)

End point title	Number of Subjects with AEs related to Rilpivirine (RPV)
-----------------	--

End point description:

Number of subjects with AEs related to RPV were assessed. An AE can be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product. The ITT population included all subjects who have taken at least 1 dose of RPV, regardless of their compliance with the protocol and adherence to the dosing regimen.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 7 years

End point values	Rilpivirine (RPV) (TMC278-C204 [C204])	RPV (TMC278-TiDP6-C209 [C209] and TMC278-TiDP6-C215 [C215])		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	119	363		
Units: Subjects	7	16		

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to 7 years

Adverse event reporting additional description:

The safety analysis set included all subjects who have taken at least 1 dose of rilpivirine (RPV), regardless of their compliance with the protocol and adherence to the dosing regimen.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	14.1
--------------------	------

### Reporting groups

Reporting group title	Rilpivirine (RPV) (TMC278-C204 [C204])
-----------------------	--

Reporting group description:

Subjects who rolled over from trial C204 continued to receive RPV 25 milligrams (mg) once daily (qd) in combination with an investigator-selected background regimen consisting of 2 nucleos(t)ide reverse transcriptase inhibitors (N[t]RTI)s starting Day 1.

Reporting group title	RPV (TMC278-TiDP6-C209 [C209] and TMC278-TiDP6-C215 [C215])
-----------------------	---

Reporting group description:

Subjects who rolled over from trial C209 and C215 continued to receive RPV 25 mg qd in combination with an investigator-selected background regimen consisting of 2 N(t)RTIs starting Day 1. In trial C209, the background regimen was fixed to tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) and in trial C215, the background regimen was selected by the investigator and contained either abacavir (ABC)/lamivudine (3TC), zidovudine (AZT)/3TC, or TDF/FTC.

<b>Serious adverse events</b>	Rilpivirine (RPV) (TMC278-C204 [C204])	RPV (TMC278-TiDP6-C209 [C209] and TMC278-TiDP6-C215 [C215])	
Total subjects affected by serious adverse events			
subjects affected / exposed	9 / 119 (7.56%)	14 / 363 (3.86%)	
number of deaths (all causes)	0	2	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adrenal Adenoma			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon Cancer			
subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Gastric Cancer			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Vascular disorders			
Thrombophlebitis			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicose Vein			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Chest Pain			
subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
Reproductive system and breast disorders			
Benign Prostatic Hyperplasia			
subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Blood Glucose Increased			

subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Injury, poisoning and procedural complications</b>			
<b>Foot Fracture</b>			
subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Hand Fracture</b>			
subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Limb Injury</b>			
subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Stab Wound</b>			
subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cardiac disorders</b>			
<b>Cardiac Hypertrophy</b>			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Coronary Artery Disease</b>			
subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Nervous system disorders</b>			
<b>Cerebrovascular Accident</b>			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Ischaemic Stroke			
subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sciatica			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Haemolytic Anaemia			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal Discomfort			
subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal Pain			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrooesophageal Reflux Disease			
subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal Haemorrhage			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholelithiasis			

subjects affected / exposed	1 / 119 (0.84%)	1 / 363 (0.28%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Renal and urinary disorders</b>			
<b>Renal Failure</b>			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Infections and infestations</b>			
<b>Bronchitis</b>			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Dengue Fever</b>			
subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Liver Abscess</b>			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Lung Infection</b>			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pneumonia</b>			
subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Syphilis</b>			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Rilpivirine (RPV) (TMC278-C204 [C204])	RPV (TMC278-TiDP6- C209 [C209] and TMC278-TiDP6-C215 [C215])	
Total subjects affected by non-serious adverse events subjects affected / exposed	24 / 119 (20.17%)	61 / 363 (16.80%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Anogenital Warts subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Vascular disorders Arteriosclerosis subjects affected / exposed occurrences (all)  Hypertension subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0  2 / 119 (1.68%) 2	1 / 363 (0.28%) 1  0 / 363 (0.00%) 0	
Pregnancy, puerperium and perinatal conditions Pregnancy subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	7 / 363 (1.93%) 7	
General disorders and administration site conditions Chest Discomfort subjects affected / exposed occurrences (all)  Chest Pain subjects affected / exposed occurrences (all)  Feeling Hot subjects affected / exposed occurrences (all)  Nodule subjects affected / exposed occurrences (all)  Oedema Peripheral	1 / 119 (0.84%) 1  1 / 119 (0.84%) 1  0 / 119 (0.00%) 0  0 / 119 (0.00%) 0  0 / 119 (0.00%) 0	1 / 363 (0.28%) 1  0 / 363 (0.00%) 0  1 / 363 (0.28%) 1  1 / 363 (0.28%) 1	

subjects affected / exposed occurrences (all)	1 / 119 (0.84%) 1	0 / 363 (0.00%) 0	
Pyrexia subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Immune system disorders Seasonal Allergy subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 2	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	2 / 363 (0.55%) 2	
Epistaxis subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Nasal Congestion subjects affected / exposed occurrences (all)	1 / 119 (0.84%) 1	0 / 363 (0.00%) 0	
Oropharyngeal Pain subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	3 / 363 (0.83%) 3	
Productive Cough subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Psychiatric disorders Abnormal Dreams subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Anxiety subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	2 / 363 (0.55%) 2	
Depression			

subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Insomnia subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	3 / 363 (0.83%) 3	
Investigations			
Alanine Aminotransferase Increased subjects affected / exposed occurrences (all)	1 / 119 (0.84%) 1	3 / 363 (0.83%) 4	
Aspartate Aminotransferase Increased subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 2	
Blood Cholesterol Increased subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	2 / 363 (0.55%) 2	
Blood Creatine Phosphokinase Increased subjects affected / exposed occurrences (all)	1 / 119 (0.84%) 1	0 / 363 (0.00%) 0	
Blood Creatinine Increased subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	2 / 363 (0.55%) 2	
Blood Lactic Acid Increased subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Blood Triglycerides Increased subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	3 / 363 (0.83%) 3	
Liver Function Test Abnormal subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Injury, poisoning and procedural complications			
Bone Fissure subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Injury			

subjects affected / exposed occurrences (all)	1 / 119 (0.84%) 1	0 / 363 (0.00%) 0	
Joint Injury subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Laceration subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Skin Injury subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Nervous system disorders Carpal Tunnel Syndrome subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Cluster Headache subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Disturbance in Attention subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Headache subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	4 / 363 (1.10%) 4	
Paraesthesia subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Blood and lymphatic system disorders Lymphadenopathy subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Eye disorders			

Conjunctivitis			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences (all)	0	1	
Eye Pain			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences (all)	0	1	
Gastrointestinal disorders			
Abdominal Distension			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences (all)	0	1	
Abdominal Pain			
subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)	
occurrences (all)	1	0	
Abdominal Pain Lower			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences (all)	0	1	
Abdominal Pain Upper			
subjects affected / exposed	1 / 119 (0.84%)	2 / 363 (0.55%)	
occurrences (all)	1	3	
Anal Pruritus			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences (all)	0	1	
Cheilitis			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences (all)	0	1	
Constipation			
subjects affected / exposed	0 / 119 (0.00%)	2 / 363 (0.55%)	
occurrences (all)	0	2	
Diarrhoea			
subjects affected / exposed	0 / 119 (0.00%)	2 / 363 (0.55%)	
occurrences (all)	0	2	
Enteritis			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences (all)	0	1	
Gastritis			

subjects affected / exposed occurrences (all)	1 / 119 (0.84%) 1	1 / 363 (0.28%) 1	
Gingivitis subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Nausea subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Oesophagitis subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Hepatobiliary disorders Cholecystitis subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Skin and subcutaneous tissue disorders Acne subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Alopecia subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Dermal Cyst subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Dermatitis Allergic subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 3	
Dyshidrosis subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Erythema subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Facial Wasting			

subjects affected / exposed occurrences (all)	2 / 119 (1.68%) 2	0 / 363 (0.00%) 0	
Lipoatrophy subjects affected / exposed occurrences (all)	1 / 119 (0.84%) 1	1 / 363 (0.28%) 1	
Lipodystrophy Acquired subjects affected / exposed occurrences (all)	2 / 119 (1.68%) 2	0 / 363 (0.00%) 0	
Pruritus subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Rash subjects affected / exposed occurrences (all)	1 / 119 (0.84%) 1	0 / 363 (0.00%) 0	
Seborrhoeic Dermatitis subjects affected / exposed occurrences (all)	1 / 119 (0.84%) 1	0 / 363 (0.00%) 0	
Skin Plaque subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Urticaria subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Musculoskeletal and connective tissue disorders			
Back Pain subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	2 / 363 (0.55%) 2	
Osteopenia subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Tendonitis subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
Trismus			

subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
<b>Infections and infestations</b>			
<b>Body Tinea</b>			
subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
<b>Bronchitis</b>			
subjects affected / exposed occurrences (all)	1 / 119 (0.84%) 2	0 / 363 (0.00%) 0	
<b>Chlamydial Infection</b>			
subjects affected / exposed occurrences (all)	1 / 119 (0.84%) 1	1 / 363 (0.28%) 1	
<b>Dengue Fever</b>			
subjects affected / exposed occurrences (all)	1 / 119 (0.84%) 1	0 / 363 (0.00%) 0	
<b>Eye Infection Toxoplasmal</b>			
subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
<b>Fungal Infection</b>			
subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
<b>Genital Herpes</b>			
subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	
<b>Hepatitis C</b>			
subjects affected / exposed occurrences (all)	2 / 119 (1.68%) 2	0 / 363 (0.00%) 0	
<b>Herpes Simplex</b>			
subjects affected / exposed occurrences (all)	1 / 119 (0.84%) 1	1 / 363 (0.28%) 1	
<b>Herpes Zoster</b>			
subjects affected / exposed occurrences (all)	1 / 119 (0.84%) 2	2 / 363 (0.55%) 2	
<b>Hordeolum</b>			
subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	1 / 363 (0.28%) 1	

Influenza		
subjects affected / exposed	0 / 119 (0.00%)	2 / 363 (0.55%)
occurrences (all)	0	2
Latent Tuberculosis		
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)
occurrences (all)	0	1
Lymph Node Tuberculosis		
subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)
occurrences (all)	1	0
Nasopharyngitis		
subjects affected / exposed	0 / 119 (0.00%)	2 / 363 (0.55%)
occurrences (all)	0	2
Oral Herpes		
subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)
occurrences (all)	1	0
Otitis Externa		
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)
occurrences (all)	0	1
Otitis Media		
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)
occurrences (all)	0	1
Perineal Abscess		
subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)
occurrences (all)	1	0
Periorbital Cellulitis		
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)
occurrences (all)	0	1
Pharyngitis		
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)
occurrences (all)	0	1
Respiratory Tract Infection Viral		
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)
occurrences (all)	0	1
Syphilis		
subjects affected / exposed	2 / 119 (1.68%)	2 / 363 (0.55%)
occurrences (all)	3	2

Tonsillitis			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences (all)	0	1	
Upper Respiratory Tract Infection			
subjects affected / exposed	0 / 119 (0.00%)	3 / 363 (0.83%)	
occurrences (all)	0	3	
Urinary Tract Infection			
subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)	
occurrences (all)	1	0	
Metabolism and nutrition disorders			
Decreased Appetite			
subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)	
occurrences (all)	1	0	
Diabetes Mellitus			
subjects affected / exposed	1 / 119 (0.84%)	0 / 363 (0.00%)	
occurrences (all)	1	0	
Hypercholesterolaemia			
subjects affected / exposed	1 / 119 (0.84%)	1 / 363 (0.28%)	
occurrences (all)	3	3	
Hyperglycaemia			
subjects affected / exposed	1 / 119 (0.84%)	1 / 363 (0.28%)	
occurrences (all)	1	3	
Hyperuricaemia			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences (all)	0	1	
Vitamin D Deficiency			
subjects affected / exposed	0 / 119 (0.00%)	1 / 363 (0.28%)	
occurrences (all)	0	1	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
05 May 2011	Amendment 1, issued on 5 May 2011, was considered substantial and the overall reason for the amendment was to replace the serum pregnancy test by a urine pregnancy test, add a reminder for the human leukocyte antigen (HLA)-B*5701 allele testing and viral genotype determination, switching of background nucleos(t)ide reverse transcriptase inhibitors [N(t)RTI]s from the roll-over visit onwards was allowed, effective methods of birth control for male and female subjects were updated and the withdrawal criteria were updated.
28 November 2016	Amendment 3, issued on 28 November 2016 (with country-specific amendments in South Africa and Chile [25 July 2017]), was considered substantial and the overall reason for the amendment was the simplification of the study and the reduction of study-related activities to a minimum for the limited number of subjects remaining in this study. The main component of the study remained to allow subjects who experienced and were expected to continue experiencing clinical benefit from rilpivirine (RPV) treatment to have continued access to RPV in a simplified study setting or to be switched to local (RPV-based) treatment options or local standard of care, as appropriate.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Not all AEs were collected; AEs considered related to RPV, leading to discontinuations, SAEs, or grade 3/4 events of rash regardless of causality were collected; discontinuation rate was > 90 percent which makes interpretation of results difficult.

Notes: